Non-Small Cell Lung Cancer

Investigators sought to determine if docetaxel plus cisplatin maintenance therapy was effective among Asian patients with non-small cell lung cancer.

Investigators sought to evaluate the role of mean heart disease and left anterior descending dose in predicting the risk of major cardiac adverse events in patients with non-small cell lung cancer.

Researchers report findings from the double-blind, phase 3 CheckMate 451 trial of nivolumab plus ipilimumab, nivolumab monotherapy, or placebo in patients with extensive-disease small cell lung cancer.

Investigators conducted a retrospective study that included data from 145 patients who underwent treatment with nivolumab or pembrolizumab for advanced non-small cell lung cancer.

Investigators conducted an integrated analysis of phase 1 and 2 trials assessing the efficacy of entrectinib among patients with ROS1 fusion-positive non-small cell lung cancer

A multicenter, phase 2 trial will assess the efficacy and safety of osimertinib among patients with isolated CNS or systemic progression of EGFR mutation-positive non-small cell lung cancer after treatment with an EGFR tyrosine kinase inhibitor.

A team of investigators conducted a retrospective study to assess outcomes with the use of chemotherapy in patients 80 years of age and older diagnosed with metastatic non-small cell lung cancer.

A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.

Investigators conducted the open-label, multicenter, single-arm phase 2 NEJ027 trial to assess outcomes in older patients with EGFR-mutated, advanced NSCLC treated with afatinib.